AI in GMP Manufacturing: A Practical Guide for Quality Professionals

What “AI in GMP” actually means in practice

The term AI covers a wide spectrum of capabilities, and not all of them are equally suitable for regulated environments.

At one end, you have narrow, deterministic models: classifiers trained to detect specific defects, regression models predicting a process parameter, anomaly detection algorithms flagging unusual sensor readings. These have well-understood behaviour, can be tested with defined acceptance criteria, and fit reasonably well within existing validation frameworks.

At the other end, you have large language models (LLMs) and generative AI: systems that can read a deviation report, draft an investigation summary, retrieve the relevant SOP, and suggest a CAPA. These are genuinely useful, but they are probabilistic, non-deterministic, and difficult to validate in the traditional GMP sense of the word.

Most of the practical value for quality professionals right now sits in a middle ground: using AI to orchestrate tasks, aggregate evidence, and support human decision-making, rather than to make decisions autonomously.

Where AI actually adds value in QA workflows

The highest-value applications share a common pattern: they tackle work that is time-consuming, repetitive, and dependent on pulling information together from multiple systems. These are also the areas where human error is most likely, not because quality professionals are careless, but because reconciling data across an MES, LIMS, QMS, and historian is genuinely hard.

Batch release evidence assembly is a good example. Before a batch can be released, someone needs to confirm that equipment was calibrated, environmental monitoring was within limits, all deviations are closed or assessed, lab results meet specification, and dozens of other checks are complete. Today, that process often involves navigating multiple systems and manually verifying each item. An AI system can assemble this evidence packet automatically, flag anything missing or inconsistent, and present it to the QP or quality unit for review. The release decision stays with the human while the tedious information-gathering is automated.

Deviation investigation support is another strong use case. When a deviation is logged, an AI system can extract structured information from the free-text description, link it to relevant equipment records and historian data, and search historical deviations for similar incidents. This can meaningfully accelerate the early stages of an investigation and improve consistency across sites or investigators.

CAPA tracking and effectiveness monitoring is unglamorous but important. AI can decompose an agreed CAPA into tasks, route approvals, track due dates, and trigger effectiveness checks, reducing the administrative overhead that often causes CAPA programmes to slip.

Continuous process verification and anomaly detection is where narrower, validated models shine. A model trained to detect multivariate anomalies in CPP/CQA data can surface process drift earlier than traditional univariate control charts, creating an opportunity to intervene before a batch is affected.

The regulatory picture: what you need to know

The regulatory landscape for AI in GMP is evolving quickly, and the details matter.

In the EU, any computerised system used in GMP activities falls under Annex 11. This means validation, audit trails, access controls, periodic evaluation, and supplier oversight are all required regardless of whether the system uses AI. AI does not create a special exemption from these requirements.

The draft EU GMP Annex 22, published for consultation in July 2025, adds AI-specific requirements on top of Annex 11. Its scope is important to understand carefully. It focuses on static, deterministic models used in critical GMP applications: classification, prediction, process monitoring. It explicitly notes that dynamic/continuously learning models, probabilistic-output models, and generative AI/LLMs should not be used in critical GMP applications. If used for non-critical tasks, a documented human-in-the-loop responsibility is expected.

A common misreading is to interpret this as a blanket prohibition on LLMs in GMP. That is not the correct interpretation. LLMs are out of scope for Annex 22, not forbidden by it. They fall back to the existing GMP framework: Annex 11, data integrity requirements, and the general principle that any system used in GMP must be fit for intended use, validated (risk-based), controlled, and traceable. The practical implication is that LLMs (today!) are realistically suited to non-critical, human-reviewed support roles, not to autonomous decision-making in quality-critical processes.

In the US, 21 CFR Part 211 and Part 11 apply. FDA's data integrity guidance requires that records created by computerised systems maintain ALCOA principles: attributable, legible, contemporaneous, original, and accurate. Any AI system that creates or modifies GMP-relevant records must satisfy these requirements.

ICH Q9 and Q10 provide the risk management and quality system framework that should govern how AI is integrated: intended use drives risk classification, which drives validation depth, change control, and monitoring.

The two-lane architecture that makes compliance practical

A useful way to think about AI deployment in GMP is a two-lane model.

Lane A is for critical GMP applications: anything that directly affects patient safety, product quality, or data integrity. Here, only locked, static, validated models should be used. Think narrow classifiers for defect detection, anomaly detection with defined thresholds, or supervised models for specific, validated use cases. These require full validation per Annex 11/22, including defined acceptance criteria, independent test data, explainability capture, drift monitoring, and change control before any update.

Lane B is for non-critical GMP support: drafting, summarising, retrieving, and orchestrating. This is where LLM-based tools live. The key controls are human review before any output influences a GMP record, auditable prompt and output logging, and clear procedural definition of what the tool can and cannot do. You are not validating the LLM itself; you are validating the process around it.

Most organisations should start in Lane B. The compliance burden is lower, the value is immediate, and the experience builds the organisational capability to tackle Lane A over time.

What “human in the loop” actually requires

Human-in-the-loop is sometimes treated as a phrase that makes AI use acceptable by default. In GMP, it has specific operational meaning.

It means a qualified person reviews the AI output before it influences a GMP record or decision. It means that review is documented, with the reviewer's identity and timestamp captured in a compliant audit trail. It means the reviewer has the training, context, and authority to actually evaluate the output, not just click approve. And it means the system is designed so that the AI recommendation is clearly distinguished from the human decision.

In practice, this often means the AI generates a draft or recommendation, the QA reviewer edits, approves, and preferably both the AI output version and the approved version are retained. The eQMS or eDMS surrounding the AI tool carries the Annex 11 / Part 11 obligations.

The validation question

Quality professionals often ask: how do you validate an AI system?

For Lane A models, the approach is structured and familiar in principle, though the specifics are new. You define intended use, characterise the input space, establish test metrics and acceptance criteria, use independent test data, document explainability elements (feature attribution, confidence scores), set thresholds for “undecided” outcomes when confidence is low, and establish a drift monitoring programme. Draft Annex 22 is specific about all of this.

For Lane B LLM tools, you validate the process, not the model. This means: documented intended use with explicit boundaries, defined HITL (human in the loop) workflow, prompt templates under version control, output logging and audit trail, periodic review of outputs for quality and compliance, and change control that captures prompt changes, model version changes, and dependency updates as potentially requiring reassessment.

Neither approach is simple, but both are tractable. The mistake is trying to apply traditional software validation directly to a generative model, or avoiding AI entirely because the validation path seems unclear.

Practical starting points

For quality professionals looking to move from curiosity to action, a few principles help.

Start narrow. Pick one workflow where the value is clear and the GMP criticality is manageable. Prove the concept, build the validation documentation, and learn from it before expanding.

Treat it as a Pharmaceutical Quality System element from day one. The intended use definition, risk assessment, validation plan, and CAPA linkage all belong in the quality system from the start.

Do not let the vendor define your compliance posture. Suppliers of AI systems are often unfamiliar with Annex 11 or Part 11 requirements.

Plan for drift. Unlike traditional software, AI models can change in performance, even if no code changes. Build performance monitoring and periodic evaluation into the operating model before you go live.

Where this is heading

The EU GMP Annex 22 consultation closed in October 2025 and is under active evaluation. The regulatory frameworks are catching up to the technology, but not yet fully formed. Organisations that invest now in governance infrastructure, intended use discipline, and validation capability will be better positioned to expand AI use as the guidance matures.

The potential is real. Evidence assembly, investigation support, and process monitoring are genuinely better candidates for AI than most enterprise knowledge work, because the data is structured, the tasks are well-defined, and the value of consistency is high. Getting there requires treating AI with the same rigour applied to every other GMP system.